Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

PYXS

NASDAQ

Pyxis Oncology (PYXS)

3.27 USD +8.83% vs prior close Sep 10, 2026
Pyxis Oncology, Inc. price graph
13 sessions
4.5 2.5 24 Aug 10 Sep

The line runs 3 USD on 24 August through 3.27 USD on 10 September, on a scale from 2.5 to 4.5. Days the market did not trade hold the previous close, flat.

Market cap
390.5M USD
Revenue, year to Dec 2025
13.9M USD
EPS, diluted, year to Dec 2025
−1.28 USD
52-week range
1.04 USD – 5.34 USD
Avg volume
88.7K

as of Sep 10, 2026

Have Pyxis Oncology (PYXS) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, Pyxis Oncology insiders reported 1 open-market purchase and no sales (SEC Form 4).

Form 4, 90 days to 22 Nov 2026, newest reported trade 1 Oct 2026

1buys
0sells
0other filings
Have Pyxis Oncology (PYXS) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
01 Oct 2026GordonMD Global Investments LP10% OwnerBuy5,517,000—

Which funds hold Pyxis Oncology (PYXS)?

7 of the 45 institutional funds we track reported a Pyxis Oncology position for the quarter ended 30 Sep 2026 — a combined 6.3M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Pyxis Oncology (PYXS)?
FundPositionSharesValueShares q/q
Millennium ManagementAdded831,7001.9M USD+256.9%
Marshall WaceHeld (±25%)760,0931.8M USD−8.5%
Soros Fund ManagementNew position476,1131.1M USD
Renaissance TechnologiesTrimmed367,780857K USD−52.4%
Citadel AdvisorsAdded198,431462K USD+319.4%
Two Sigma InvestmentsTrimmed46,700109K USD−44.4%
Balyasny Asset ManagementNew position19,36145K USD
Point72 Asset ManagementExited

What has been filed or recorded for Pyxis Oncology (PYXS)?

The filings we hold for Pyxis Oncology, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 29 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Pyxis Oncology (PYXS)?
And
29 Oct 2026Fails to deliverShares failed to deliver3,000 shares6K USD notional · 0.003% of shares out
22 Oct 2026Fails to deliverShares failed to deliver14,091 shares25K USD notional · 0.012% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.24 USD
30 Sep 2026FinancialsTotal assets76.8M USDat period end
30 Sep 2026FinancialsTotal equity41.3M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.40 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.37 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −1.28 USDRevenue $14M
31 Dec 2025FinancialsRevenue13.9M USDfiscal year
31 Dec 2025FinancialsNet income−79.6M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−1.28 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.35 USDRevenue $3M
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.30 USDRevenue $3M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.35 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −1.32 USDRevenue $16M

What do people ask about Pyxis Oncology (PYXS)?

From live data
What did Pyxis Oncology shares close at?3.27

Pyxis Oncology closed at 3.27 USD on 10 Sep 2026, up 8.83% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Pyxis Oncology’s market cap?390.5M

Pyxis Oncology is worth 390.5M USD by market value as of 10 Sep 2026, which is the share price times the shares on issue from its SEC filings.

What is Pyxis Oncology’s revenue?13.9M

Pyxis Oncology reported revenue of 13.9M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Pyxis Oncology insiders bought or sold shares recently?1 purchase

In the 90 days to 22 Nov 2026, Pyxis Oncology insiders reported 1 open-market purchase and no sales (SEC Form 4). See Insiders

Which funds own Pyxis Oncology?7 of 45

7 of the 45 funds we track reported a Pyxis Oncology position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, Marshall Wace and Soros Fund Management. See Funds

When did Pyxis Oncology last report earnings?−0.24

Pyxis Oncology last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.24 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words